Stanford University, Palo Alto, California, USA.
Curr Opin Obstet Gynecol. 2024 Dec 1;36(6):394-399. doi: 10.1097/GCO.0000000000000988. Epub 2024 Sep 12.
The purpose of this review is to summarize the historical context and recent literature that contribute to the debate about preventive strategies for Rhesus (Rh)-alloimmunization in abortion are.
Recent studies repeatedly demonstrate that the risk of Rh-alloimmunization in first trimester abortion care is very low.
Recent high-quality studies have demonstrated the physiologic presence of fetal red blood cells in maternal circulation even prior to abortion. Thus, establishing the low utility of Rh immunoglobulin prior to abortion before 12 weeks of gestation. There is yet to exist a consensus guideline that balances the desire to prevent a rare devastating outcome and the need to create practical guidelines based on evidence-based risk assessments.
本文综述了导致流产中预防 Rh 同种免疫策略相关争议的历史背景和近期文献。
近期的研究反复证明,在流产的早期妊娠护理中 Rh 同种免疫的风险非常低。
最近的高质量研究表明,即使在流产之前,胎儿红细胞也存在于母体循环中。因此,在妊娠 12 周之前,流产前使用 Rh 免疫球蛋白的效用很低。目前还没有一项共识指南能够平衡预防罕见灾难性结局的愿望和基于循证风险评估制定实用指南的需求。